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Abstract
Aim: Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment
compared to carvedilol on indices of insulin resistance. The aim of this study was to examine the effect of
metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with
type 2 diabetes.
Method: 24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or
50 mg carvedilol daily. Endothelium-dependent vasodilation was assessed by using venous occlusion
plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin. Insulin-stimulated
endothelial function was assessed after co-infusion of insulin for sixty minutes. Vaso-reactivity studies were done
before and after the two-month treatment period.
Results: Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage
change in forearm blood-flow was 60.19% ± 17.89 (at the highest serotonin dosages) before treatment and
-33.80% ± 23.38 after treatment (p = 0.007). Treatment with carvedilol did not change insulin-stimulated
endothelial function. Endothelium-dependent vasodilation without insulin was not changed in either of the two
treatment groups.
Conclusion: This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while
blunted during treatment with metoprolol in patients with type 2 diabetes.
Trial registration: Current Controlled Trials NCT00497003
Introduction
Type 2 diabetes is associated with a high risk of cardio-
vascular complications [1]. Beta-blockers are generally
considered to worsen metabolic control in patients with
diabetes, but the GEMINI (The Glycemic Effects in Dia-
betes Mellitus: Carvedilol-Metoprolol Comparison in
Hypertensives) study demonstrated improved metabolic
control in patients with type 2 diabetes and hyperten-
sion treated with carvedilol as compared with metopro-
lol [2]. Further, in the presence of heart failure,
carvedilol was shown to be associated with improved
survival (The Carvedilol or Metoprolol European Trial
[COMET]) and with fewer cases of new onset diabetes
compared to metoprolol tartrate [3,4].
These results lead us to hypothesize that carvedilol
and metoprolol might have different vascular effects
related to insulin sensitivity. Endothelial dysfunction is
thought to be one of the earliest changes in the patho-
genesis of atherosclerosis [5], and is associated with an
increased risk of cardiovascular disease [6]. Diabetes and
insulin resistance are associated with endothelial dys-
function [7] as well as reduced insulin sensitivity of the
endothelium - reduced insulin-stimulated endothelial
function [8,9]. Further, improved regulation of glucose
control with insulin in patients with type 2 diabetes is
known to be associated with fewer vascular complica-
tions [UKPDS - (UK Prospective Diabetes Study)] [1] * Correspondence: BRIKVE01@geh.regionh.dk
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endothelial insulin sensitivity [8,9] and improved
endothelial function [10].
In this study, we hypothesized that the beneficial
effects of carvedilol compared to metoprolol could be
related to an improvement of endothelial function and/
or endothelial insulin resistance in patients with type 2
diabetes.
Methods
Study group
A total of 19 patients with type 2 diabetes and 10 lean
healthy controls were included and completed the study.
Measurements of endothelial function as well as insulin
stimulated endothelial function were performed in all
individuals. All patients with type 2 diabetes met the
diagnostic criteria for type 2 diabetes, as defined by
the American Diabetes Association (ADA) [11]. None of
the patients were treated with insulin. Patients with a
history of atherosclerosis or heart disease of any cause
were excluded, as were patients with known diabetic
retinopathy, nephropathy or neuropathy. Additional
exclusion criteria were known intolerance to beta-
blocker treatment, bradycardia, hypotension and
untreated hypertension. Patients with severe asthma or
patients who received treatment with beta-agonists were
also excluded from the study. None of the persons in
the control group received any kind of medication and
had no history of cardiovascular disease. Diabetes,
hypertension and smoking were also exclusion criteria
in the healthy control group.
Patients were recruited by advertisement in a local
newspaper, and all patients gave written informed con-
sent before entering the study. The study was approved
by the ethics committee of the city of Copenhagen (ref
KF 02-071/03), as well as the Danish Medicines Agency
(ref 2612-2423).
Design
Patients with type 2 diabetes were randomized to
receive treatment with metoprolol succinate (N = 10;
SeloZok, AstraZeneca, Cheshire, England) or carvedilol
(N = 9; Dimitone, Roche, Basel, Switzerland). The target
dose was 200 mg once daily for metoprolol and 25 mg
twice daily for carvedilol in order to secure equipotent
doses of the two beta-blockers. The study was designed
as an open parallel group study. Before and after the
two-month treatment period, endothelial function and
insulin-stimulated endothelial function were measured.
Venous occlusion plethysmography
Forearm blood-flow was measured by using venous
occlusion plethysmography as described previously
[8]. All measurements were done blinded to the treat-
ment protocol. The patients did not take their usual
medication in the morning on the day of examination.
All examinations were done after an overnight fast and
abstinence from smoking. The patients lay supine in a
quiet room, with the temperature kept constant. Both
forearms were placed at a horizontal level with the right
atrium while measurements were done.
An arterial cannula with an external diameter of
1 mm was inserted into the brachial artery, preferen-
tially in the non-dominant arm. The arterial cannula
was used for intra-arterial infusions and blood pressure
measurement.
To assess endothelium-dependent vasodilation, forearm
blood-flow was measured during infusion of increasing
doses of serotonin (7, 21, 70 ng/min) [Serotonin (Clinalfa,
Läufelfingen, Switzerland)]. For each dose, serotonin was
infused for 4 minutes, before blood-flow measurements
were done, to obtain a steady state. Measurements of fore-
arm blood-flow were done simultaneously in both the
infused and the non-infused arm, and presented as the
ratio between the two arms. Endothelium-independent
vasodilation in the forearm was examined by exchanging
serotonin infusion with increasing doses of sodium nitro-
prusside [Nitropress (Abbott Laboratories, North Chicago,
IL)]. The doses of sodium nitroprusside (0.5, 1 and 1.5 μg/
min) were chosen according to previous studies, to ensure
matching blood-flow to the flows obtained by studies of
serotonin in healthy people [12,13].
Insulin-stimulated endothelial function was assessed
by an intra-arterial co-infusion of serotonin and insulin.
Insulin [Actrapid (Novo Nordisk Scandinavia, Malmö,
Sweden) in a 1% human albumin solution (vehicle)] was
infused at a rate of 0.05 mU/kg body weight/min for
60 minutes and followed by co-infusion of serotonin to
achieve a dose-response study as described above. To
determine the NO-dependent fraction of insulin-stimu-
lated serotonin response, an intra-arterial co-infusion of
L-NMMA [L-NMMA (Clinalfa)] was infused for 10 min,
with a dose of 3.3 mg/min, followed by a dose-response
study with serotonin.
To allow wash-out between measurements, all infu-
sions were stopped for at least 30 minutes while saline
was infused at a rate of 60 ml/h to maintain the cannula
patent.
All blood-flow measurements are presented as a rela-
tive blood-flow given as the actual flow (ml/min) of the
infused arm as a proportion to the non-infused arm.
This has been done to correct for the systemic changes
in flow during the day and changes in between the two
days of examinations, irrespective of the infusions of
substances.
Statistics
This study is a small size study with the purpose of
finding differences between both serotonin stimulated
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endothelial function in groups. Endothelial function is
presented as a mean of flow. Means of flow were com-
pared with a paired t-test at baseline before treatment
and again after treatment with either of the two beta
blockers. Dose-response curves were compared by com-
bined analysis of variance and covariance (mixed model
analysis). Experimental subject and the interaction
between experimental subject and dose of serotonin
were entered as random variables whereas study group
(metoprolol or carvedilol) dose of serotonin were
entered as fixed terms. Calculations were performed
with the SAS (Statistical Analysis Systems) version 9.1
Results
Characteristics of the two treatment groups as well as the
healthy control group are shown in Table 1. No signifi-
cant differences were seen between the two diabetes
groups at baseline. Compared to the healthy control
group, the type 2 diabetic patients had a higher BMI and
higher fasting glucose as well as glycosylated hemoglobin,
as expected. There were no significant differences in total
cholesterol between the groups, but the type 2 diabetes
group tended to have higher triglycerides- and well as
LDL-levels. The actual p-values for the changes between
the groups are presented in Table 1.
In the group of patients treated with carvedilol or meto-
prolol, 3 patients were smokers whereas there were no
smokers in the control group. The patients in the con-
trol group were slightly younger than the patients in the
two groups with type 2 diabetes.
Twenty four patients were randomized in the study.
Of those, five patients were withdrawn from the study:
One because of technical difficulties in reading the
results of the study and two because of difficulties with
the arterial cannula. Two patients were withdrawn from
the study due to adverse reactions during the treatment
period: One patient who developed a severe cutaneous
allergic reaction during treatment with carvedilol and
one patient who had a minor stroke during treatment
period with metoprolol. Two additional patients with
adverse reactions during the treatment were not with-
drawn from the study and results of their vaso-reactivity
studies were included. Of these, one patient developed
Table 1
T2DM
Carvedilol
(N = 9)
T2DM
Metoprolol
(N = 10)
Healthy
controls
(N = 10)
P Carvedilol vs.
metoprolol
P Carvedilol vs.
control
P Metoprolol vs.
control
Age (years) 58.9 ± 2.67 58.0 ± 3.02 47.6 ± 1.89 0.83 0.003 0.009
Sex (M/F) 7/2 9/1 5/5
Smoking (%) 1 (11) 2 (20) 0
Oral hypoglycaemic*
(%)
8 (89) 9 (90) 0
Aspirin (%) 0 0 0
Statins (%) 3 (33) 5 (50) 0
ACE inhibitors/AT2 B
(%)
4 (44) 3 (30) 0
Body weight (kg) 89.72 ± 7.10 97.9 ± 5.76 75.62 ± 4.24 0.38 0.10 0.006
BMI (Kg/m²) 29.26 ± 1.76 32.22 ± 1.84 24.4 ± 0.93 0.27 0.02 0.002
Systolic BP (mm Hg) 142.4 ± 5.09 143.4 ± 5.12 0.90
Diastolic BP (mm Hg) 71.4 ± 2.59 70.5 ± 4.67 0.87
Heart rate (beats/min) 67.1 ± 2.16 69.4 ± 3.31 0.58
Fasting glucose
(mmol/L)
8.76 ± 0.78 8.54 ± 1.11 5.2 ± 0.17
Fasting insulin (μU/l) 10.20 ± 3.20 10.82 ± 2.14
Hb A1c (%) 7.6 ± 0.59 7.29 ± 0.42 5.24 ± 0.10 0.67 0.0004 0.0002
Total Cholesterol
(mmol/L)
4.12 ± 0.28 3.93 ± 0.25 4.5 ± 0.29 0.62 0.36 0.15
LDL (mmol/L) 2.29 ± 0.31 2.25 ± 0.27 2.70 ± 0.26 0.93 0.29 0.22
HDL (mmol/L) 1.19 ± 0.06 1.09 ± 0.10 1.40 ± 0.14 0.42 0.19 0.09
TG (mmol/L) 1.41 ± 0.27 1.33 ± 0.26 0.90 ± 0.17 0.83 0.12 0.18
CRP (mmol/L) 3.00 ± 0.44 6.80 ± 2.38 2.00 ± 0.58 0.15 0.10 0.05
* Oral hypoglycaemic: Included patients taking both metformin and sulfonylurea
Abbreviations:T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers;
BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride;
CRP: C-Reactive Protein.
Kveiborg et al. Cardiovascular Diabetology 2010, 9:21
http://www.cardiab.com/content/9/1/21
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patient in the metoprolol group had a mild episode of
depression.
Ten patients with type 2 diabetes received treatment
with metoprolol succinate, mean daily dose of 175 mg,
and 9 patients received treatment with carvedilol, mean
daily dose of 44 mg for a period of 2 months. Doses of
metoprolol succinate and carvedilol were equivalent
in this study which corresponds with a dose of 88% of
target dose for both drugs.
Changes in baseline characteristics after treatment with
either carvedilol or metoprolol are presented in Table 2
and 3 respectively. After treatment with metoprolol,
there was a significant mean increase in body weight of
1.8 kg (1.8% change) (p = 0.02), whereas a non-significant
mean increase in body weight of 0.6 kg (0.6% change) was
seen in the carvedilol group (p = 0.43).
Fasting blood glucose, fasting insulin and glycosylated
hemoglobin remained unchanged at the end of the
treatment with any of the two beta-blockers (Table 2
and 3).
Systolic blood pressure did not change with metoprolol
while carvedilol treatment tended to lower systolic blood
pressure although this change was non-significant
(142.4 ± 5.09 mmHg before treatment versus 136.9 ±
5.80 mmHg after treatment) (-3.7% change) (p = 0.38).
Diastolic blood pressure decreased after treatment with a
beta-blocker to a similar level in both treatment groups;
from 71.4 ± 2.59 mmHg to 61.3 ± 3.13 mmHg (-14.1%
change) in the carvedilol group (p < 0.05) and 70.5 ± 4.67
mmHg to 64.0 ± 3.84 mmHg (-9.2% change) in the meto-
prolol group (p < 0.05), while resting heart rate decreased
only significantly in the carvedilol group from 67.1 ± 2.16
to 60.7 ± 1.74 (-9.5% change) (p < 0.05).
Endothelial function
The patients with type 2 diabetes had a significant
lower response to serotonin than the healthy control
group (Fig. 1). Relative flow (±SEM) at baseline at the
three dose levels of serotonin infusion were 1.17 ±
0.08; 1.26 ± 0.11; 1.62 ± 0.16 and 1.84 ± 0.20 in the
group of patients with type 2 diabetes compared to
1.12 ± 0.12; 1.15 ± 0.11; 1.71 ± 0.15 and 2.69 ± 0.23 in
the healthy control group (p = 0.002). Also, the insu-
lin-stimulated serotonin response was significantly
lower in patients with type 2 diabetes (Fig. 2): The per-
centage increase in blood-flow after co-infusion of
insulin compared to serotonin alone was 45.96 ±
11.56%; 67.40 ± 18.11% and 84.57 ± 25.73% in the
healthy control group and 26.48 ± 7.74%; 26.40 ±
11.52% and 19.75 ± 13.87% (p = 0.02) in the group of
patients with type 2 diabetes.
Treatment with carvedilol or metoprolol did not change
endothelium-dependent vasodilation. Before treatment
the relative blood-flow was 1.25 ± 0.14; 1.24 ± 0.08;
1.64 ± 0.16 and 1.96 ± 0.14 in the carvedilol group at
serotonin doses of 0, 7, 21 and 70 ng/minute respec-
tively. After two months treatment with carvedilol, the
relative blood-flow was 1.32 ± 0.14; 1.26 ± 0.18; 1.67 ±
0.15 and 2.35 ± 0.29 (P = 0.22) (Fig. 3). In the metopro-
lol group relative blood-flow was 1.10 ± 0.08; 1.28 ±
0.21; 1.60 ± 0.26 and 1.73 ± 0.20 before treatment and
1.03 ± 0.05; 1.12 ± 0.09; 1.62 ± 0.17 and 2.13 ± 0.17
after two months treatment (p = 0.30) (Fig. 4).
After two months treatment with carvedilol the percen-
tage increase in blood-flow after co-infusion with insulin
was unchanged whereas treatment with metoprolol
deteriorated the insulin-stimulated response significantly
(Fig. 5). The percentage change after co-infusion of
Table 2 Changes in baseline characteristics seen after treatment with carvedilol
Before carvedilol
(N = 9)
After carvedilol
(N = 9)
% Change after treatment P-value
Body weight (kg) 89.72 ± 7.10 90.32 ± 7.39 0.6% 0.43
BMI (Kg/m²) 29.26 ± 1.76 29.48 ± 1.87 o.8% 0.39
Systolic BP (mm Hg) 142.4 ± 5.09 136.9 ± 5.80 -3.7% 0.38
Diastolic BP (mm Hg) 71.4 ± 2.59 61.3 ± 3.13³ -14.1% 0.003
Heart rate (beats/min) 67.1 ± 2.16 60.7 ± 1.74³ -9.5% 0.02
Fasting glucose (mmol/L) 8.61 ± 0.78 9.66 ± 1.31 12.2% 0.20
Fasting insulin (μU/L) 10.20 ± 3.20 13.75 ± 8.42 34.8% 0.68
Hb A1c (%) 7.6 ± 0.59 7.66 ± 0.76 0.8% 0.95
Total Cholesterol (mmol/L) 4.12 ± 0.28 4.48 ± 0.35 8.7% 0.06
LDL (mmol/L) 2.29 ± 0.31 2.5 ± 0.30 9.2% 0.10
HDL (mmol/L) 1.19 ± 0.06 1.24 ± 0.09 4.2% 0.37
TG (mmol/L) 1.41 ± 0.27 1.57 ± 0.28 11.3% 0.38
CRP (mmol/L) 3.00 ± 0.44 2.89 ± 0.26 -3.7% 0.68
T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass
Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive
Protein.
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Page 4 of 11insulin in the group of patients treated with metoprolol
was 29.77% ± 29.83; 31.44% ± 31.01 and 60.19% ± 17.89
before treatment and 41.46% ± 20.09; -9.45% ± 14.64
and -33.80% ± 23.38 after treatment (p = 0.007) at the
three dose levels of serotonin respectively.
Endothelium independent vasodilation, assessed after
infusions of sodium nitroprusside, was unchanged after
treatment with either of the two beta blockers (Fig 6
and 7).
L-NMMA co-infusion abolished the increase in blood-
flow during serotonin and insulin co-infusion in both
the carvedilol and metoprolol group at baseline and was
not changed by either treatment with carvedilol or
metoprolol.
Table 3 Changes in baseline characteristics seen after treatment with metoprolol
Before metoprolol
(N = 10)
After metoprolol
(N = 10)
% Change after treatment P-value
Body weight (kg) 97.9 ± 5.76 99.7 ± 5.88 1.8% 0.02
BMI (Kg/m²) 32.22 ± 1.84 32.84 ± 1.95 1.9% 0.03
Systolic BP (mm Hg) 143.4 ± 5.12 142.8 ± 5.56 -0.4% 0.90
Diastolic BP (mm Hg) 70.5 ± 4.67 64 ± 3.84 -9.2% 0.04
Heart rate (beats/min) 69.4 ± 3.31 65.5 ± 6.74 -5.6% 0.01
Fasting glucose (mmol/L) 8.53 ± 0.99 8.67 ± 1.14 1.6% 0.90
Fasting insulin (μU/L) 10.82 ± 2.14 14.83 ± 4.75 37.1% 0.60
Hb A1c (%) 7.29 ± 0.42 7.51 ± 0.62 3.0% 0.77
Total Cholesterol (mmol/L) 3.93 ± 0.25 3.81 ± 0.27 -3.1% 0.59
LDL (mmol/L) 2.25 ± 0.27 1.99 ± 0.32 -11.6% 0.17
HDL (mmol/L) 1.09 ± 0.10 1.06 ± 0.12 -2.8% 0.10
TG (mmol/L) 1.33 ± 0.26 1.71 ± 0.35 28.6% 0.04
CRP (mmol/L) 6.80 ± 2.38 4.56 ± 1.56 -32.9% 0.19
T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass
Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive
Protein.
Figure 1 Endothelial function presented as relative forearm blood-flow at baseline was lower in the group of patients with type 2
diabetes, compared to the healthy control group. Forearm blood-flow is presented as a proportion between the infused and the non-
infused arm.
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Page 5 of 11Figure 2 At baseline, serotonin-stimulated forearm blood flow was enhanced by insulin in the healthy control group while this
response was blunted in patients with type 2 diabetes.
Figure 3 Forearm blood-flow was not changed in the group of patients with type 2 diabetes after treatment with carvedilol (white
circle) compared to the response before treatment (black circle).
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The main result of this study is that insulin-stimulated
endothelial function remained preserved during treat-
ment with carvedilol and blunted during treatment with
metoprolol, whereas endothelium-dependent and
endothelium-independent vasodilation was unchanged
in both groups.
T h el a c ko fe f f e c to fc a r v e d i l o li ne n d o t h e l i a lf u n c t i o n
in the absence of stimulation with insulin, is somehow in
contrast with a recent study where carvedilol has shown
to improve endothelial function assessed by measures on
albuminuria and measures on brachial reactivity by ultra-
sound, compared with metoprolol [14]. It cannot be
ruled out that we could have demonstrated an improve-
ment of the serotonin-stimulated flow in a larger popula-
tion but intra-arterial co-infusion of insulin and
serotonin provides a unique possibility to assess specifi-
cally insulin sensitivity of the endothelium [15], whereby
it further supports that an improved vascular nitric oxide
reactivity is the main mechanism that accounts for the
beneficial effects of carvedilol. This is additionally sup-
ported by the observation in our study that co-infusion
of serotonin, insulin and L-NMMA totally abolished
vasodilation both before and after treatment with either
of the two beta blockers. These findings could not be
explained by changes in either blood pressure or meta-
bolic glucose control. Furthermore, it is possible that a
lower CRP measured at baseline in the carvedilol group
accounts for the lack of potential to improve serotonin
response (Table 1). Nevertheless, this difference at base-
line rather strengthens our study, since in spite of a
“healthier” condition of the carvedilol group it was possi-
ble to improve the insulin-stimulated serotonin response.
Insulin resistance is an independent risk factor of devel-
oping cardiovascular disease [16]. Diabetes is a condition
with insulin resistance including vascular insulin resis-
tance [8]. This was also found in our study. By improving
metabolic glucose control in patients with type 2 dia-
betes, vascular insulin resistance also improves [8]. Insu-
lin stimulated vasodilation has been found to be NO
dependent [17]. A blunted insulin stimulated vasodilation
itself leads to vasoconstriction and is thereby proathero-
genic. Co-morbidity with hypertension, ischemic heart
disease or heart failure is common in patients with type 2
diabetes. Treatment with beta adrenergic blockers is
therefore often necessary to reduce their total risk of car-
diovascular disease. As insulin resistance serves as a key
role between diabetes and cardiovascular disease, it is of
Figure 4 Forearm blood-flow was not changed in the group of patients with type 2 diabetes after treatment with metoprolol (white
circle) compared to the response before treatment (black circle).
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Page 7 of 11Figure 5 The percentage increase in forearm blood-flow after co-infusion of serotonin and insulin was decreased after treatment with
metoprolol (white triangle) compared to the blood-flow before this treatment (black triangle). The increase in forearm blood-flow was
not changed by treatment with carvedilol.
Figure 6 Forearm blood-flow after stimulation with sodium nitroprusside was unchanged after treatment with carvedilol.
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Page 8 of 11importance that beta blocker treatment does not aggra-
vate insulin resistance. Vascular insulin resistance dete-
riorates glucose supply and thereby utilization in
peripheral tissue. Vascular insulin resistance may there-
fore be an important factor when treating patients with
type 2 diabetes or metabolic syndrome. The importance
of the findings in this study for the prognosis of patients
is unknown, but the result could inspire to further stu-
dies of the importance of vascular insulin sensitivity
given the favorable effects of carvedilol compared to
metoprolol observed in the COMET study (The Carvedi-
lol or Metoprolol European Trial) [3,4].
Carvedilol has been found superior to metoprolol in
the control of glucose metabolism in patients with type
2 diabetes and hypertension [2]. Also studies show that
carvedilol does not deteriorate insulin resistance, as it
was found in a direct comparison with metoprolol [18].
In the study by Jacob et al, insulin sensitivity was mea-
sured by use of the euglycemic hyperinsulinaemic clamp
method and the study included patients with hyperten-
sion, but not diabetes. Compared to atenolol, a selective
beta-1 adrenergic receptor blocker, carvedilol has also
shown a more favorable effect on systemic glucose
metabolism [19], whereas atenolol and metoprolol both
decreased insulin sensitivity to a similar level, when
compared directly with an euglycemic hyperinsulinaemic
clamp [20]. These studies all show a systemic change in
insulin resistance, whereas our study shows that the two
beta-blockers, metoprolol and carvedilol, have a differ-
ential effect on vascular insulin sensitivity, with an
advantage in favor of carvedilol.
In the group of patients treated with metoprolol we
found an increase in body weight of 1.8 kg (p = 0.02)
after 2 months of treatment. In contrast to this, no sig-
nificant weight gain was found in the group of patients
treated with carvedilol. This is in accordance with the
weight gain seen after treatment with beta-blockers in
large clinical trials [21]. In the GEMINI trial, a signifi-
cant weight gain of 1.2 kg was found in the metoprolol
arm compared to a non-significant weight gain in the
carvedilol arm [2]; whether this can explain the general
metabolic disadvantages seen with metoprolol in large
clinical trials is uncertain. Whether the weight gain in
the metoprolol group seen in our study is associated
with deterioration of insulin-stimulated endothelial
function is also not known. An inverse association
between weight and adiponectin level has been found
[22] and low plasma-adiponectin levels are considered
to be a predictor of cardiovascular disease in patients
with type 2 diabetes [23]. In a recent study, metoprolol
was found to decrease adiponectin level in hypertensive
patients [24]. Adiponectin could play a role in the
Figure 7 Forearm blood-flow after stimulation with sodium nitroprusside was unchanged after treatment with metoprolol.
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treatment with metoprolol found in our study, and the
weight-gain seen could also be an important factor.
The beta-1 adrenergic receptor blocker atenolol causes
enhancement of endothelium-dependent vasodilation
during short time infusion and during 3 months treat-
ment [25,26]. In contrast, the non-selective beta-blocker
propranolol causes attenuation of endothelial function
during direct intra-arterial infusion and causes coronary
artery vasoconstriction [25,27,28]. Four months treat-
ment with carvedilol in patients with coronary artery
disease improved endothelial function whereas no
change was seen after short term treatment of 2 hours
[29]. The long term effect on endothelial reactivity
therefore seems to be dependent on the properties of
the beta-blockers.
Carvedilol has additional adrenergic receptor blocking
properties, beta-1, beta-2 and alfa-1, along with
antioxidative properties [30] compared to metoprolol, a
beta-blocker with beta-1 adrenergic receptor blocking
properties. The effect of carvedilol on the endothelium
may be explained by either increased endothelial NO-
production or decreased NO-breakdown. Carvedilol sti-
mulates endothelial nitric oxide production [31] and its
hemodynamic effects are blunted during complete inhibi-
tion of NO-production [32]. In type 2 diabetes, an
increased production of free radicals leads to an
increased oxidative stress to the vascular wall [33].
Therefore carvedilol may have beneficial effects on
endothelial dysfunction caused by oxidative stress in
patients with type 2 diabetes.
Vascular studies of long-term treatment with carvedilol
have shown to improve endothelial function in patients
with coronary artery disease which was attributed to the
antioxidative properties of carvedilol [34], but in a recent
study improvement of endothelial function after treatment
with carvedilol in patients with diabetes, no changes in
markers of oxidative stress could be found [35].
As described, studies show inconclusive effects of the
anti-oxidant property of carvedilol on endothelial func-
tion. We have not been able to demonstrate a benefit on
endothelial function from treatment with carvedilol in
patients with type 2 diabetes, despite the increased oxida-
tive stress in this group of patients [36]. But our study
indicates that carvedilol has supplemental effects and this
might be of importance when treating diabetic vascular
diseases; to our knowledge, this is the first study to
demonstrate a direct effect on insulin-stimulated
endothelial function in patients with type 2 diabetes,
when treated with different generations of beta-blockers.
Limitations to the study
The lack of changes in serotonin stimulated endothelial
function after treatment with carvedilol or metoprolol
m i g h tb ec a u s e db yt h es m a l ln u m b e ro fp a t i e n t s
included in the study. Nevertheless we were able to
demonstrate a difference between the insulin stimulated
endothelial function in the group of patients treated
with carvedilol and not even a trend of change in sero-
tonin stimulated endothelial function. The number of
patients included in the study might not be the only
explanation to the lack of change after beta blocker
treatment.
This a small interventional study with the purpose of
finding changes in endothelial function between groups.
Therefore changes in baseline characteristics could not
be expected to be found with a statistical significance in
this study. A large interventional study is needed to find
the actual differences in endothelial function after treat-
ment with either carvedilol or metoprolol with correc-
tion for the baseline characteristics and changes found
in this study.
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